The Premier RBQM
Industry Event:
Now Available
on Demand.

Stay ahead on AI, global regulations, and the technology reshaping risk-based quality management (RBQM)—watch the RBQMLive26 sessions on demand now.

Stay ahead on AI, global regulations, and the technology reshaping risk-based quality management (RBQM)—watch the RBQMLive26 sessions on demand now.

Couldn’t join us live?

Don’t worry. We’ve got you covered.

Dive into the on-demand recordings and catch every insight, case study, and practical strategy.
Ken Getz
Ken Getz

Executive Director and Professor,
Tufts CSDD

Miguel Valenzuela
Miguel Valenzuela

Director of Clinical Risk and Analytics,
Alnylam

Jamie O’Neill
Jamie O’Neill

Director of Operational Systems,
Takeda

Demi You
Demi You

Head of RBM and Business Capability Owner of Patient Data Monitoring,
Sanofi

Brian Barnes
Brian Barnes

Director, Risk Management Strategy,
BioNTech

Cris McDavid
Cris McDavid

Executive and Clinical Research Leader,
Parexel

Tom Whitman
Tom Whitman

Associate Director of Systems Quality and Data Integrity,
Biogen

Kris Luypaert
Kris Luypaert

Global Development Operations Inspection Excellence Lead,
Merck KGaA

What’s RBQMLive?

RBQMLive is the premier virtual event dedicated to RBQM. Held annually, it brings together industry experts, clinical trial professionals, and product innovators for deep-dive discussions into latest developments shaping RBQM. RBQMLive26 featured four sessions with exclusive insights into the future of RBQM, how to prove RBQM value, responsible AI adoption, and predictive quality management.

Our Founder and Sponsor:

CluePoints created RBQMLive to give the RBQM community a dedicated space to learn, debate, and advance the science of risk-based quality management. As the founding sponsor, CluePoints brings together the brightest minds in clinical trials, independent of any commercial agenda.

2026 sessions

2026 Sessions: Watch on Demand

SESSION 1

RBQM at a Turning Point: From Adoption to Operational Maturity E8 and E11 Potential Expansion

This session explores how RBQM has achieved widespread adoption and how companies and organizations are operationalizing risk-based approaches. The keynote examines where the industry stands today, why expectations and practices have shifted, and how regulatory tailwinds (e.g., ICH E6(R3)) and the rapid emergence of AI and real-world oversight, are redefining the RBQM landscape. From this session, you will gain a clear perspective on the next phases of RBQM and the organizational capabilities needed to succeed.

Speakers

Ken Getz

Executive Director and Professor, Tufts CSDD

Ken McFarlane

VP, Strategic Consulting, CluePoints

SESSION 2

Beyond Adoption: Proving the Value of a Mature RBQM Program (Panel)

Organizations have largely implemented RBQM, but achieving measurable value requires moving beyond compliance toward operational excellence. This discussion explores how leading sponsors are advancing their RBQM programs, overcoming common barriers, and building mature, scalable risk management practices. Panelists share lessons learned around governance, organizational change, cross-functional collaboration, and how they build and defend the business case to finance and quality leadership.

Speakers

Demi You

Head of RBM and Business Capability Owner of Patient Data Monitoring, Sanofi

Jamie O’Neill

Director of Operational Systems, Takeda

Miguel Valenzuela

Director of Clinical Risk and Analytics, Alnylam

Kyle Given

RBQM Market Owner & Strategy Lead, CluePoints

SESSION 3

Trusted AI in Clinical Operations: From Automation to Decision Intelligence

AI is rapidly moving from experimentation to practical application across clinical development. This session explores how organizations are implementing AI responsibly while improving efficiency, consistency, and decision-making. Speakers discuss governance, validation, transparency, auditability, continuous monitoring, and what sponsors need from AI vendors to confidently integrate AI into regulated clinical processes.

Speakers

Cris McDavid

Executive and Clinical Research Leader, Parexel

Brian Barnes

Director, Risk Management Strategy, BioNTech

Sas Maheswaran

Market Owner for Clinical Data Strategy, CluePoints

SESSION 4

Designing Quality: From Inspection Readiness to Predicting Risk Before First Patient (Panel)

Inspection readiness is no longer about preparing for an audit. It is about continuously understanding and managing quality risk throughout a study. This session explores how organizations are shifting from reactive compliance to predictive quality management, using historical study data and protocol intelligence to identify emerging risk before they affect execution, and increasingly to design risk out at the protocol stage. Panelists discuss how early risk visibility improves planning, oversight, and regulatory confidence.

Speakers

Kris Luypaert

Global Development Operations Inspection Excellence Lead, Merck KGaA

Tom Whitman

Associate Director of Systems Quality and Data Integrity, Biogen

Thank you to our speakers

Your RBQM Guides

We’re deeply grateful to our expert speakers for sharing their knowledge and perspectives. Special thanks to leaders from Tufts CSDD, Sanofi, Takeda, Alnylam, Parexel, BioNTech, Merck KGaA, and Biogen for delivering cutting-edge insights that are already driving meaningful change across the industry.
Tufts CSDD, Sanofi, Takeda, Alnylam, Parexel, BioNTech, Merck KGaA and Biogen
More from previous years
More from previous years

Want to Speak at the Next RBQMLive or Other CluePoints Events?

We’re looking for industry experts, innovators, and thought leaders to take the virtual stage. Submit your details using the form, and we’ll be in touch to discuss speaking opportunities.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.